Insulet Corp
NASDAQ:PODD

Watchlist Manager
Insulet Corp Logo
Insulet Corp
NASDAQ:PODD
Watchlist
Price: 262.93 USD 0.35% Market Closed
Market Cap: 18.4B USD
Have any thoughts about
Insulet Corp?
Write Note

Gross Margin
Insulet Corp

69.4%
Current
66%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
69.4%
=
Gross Profit
1.4B
/
Revenue
2B

Gross Margin Across Competitors

Country US
Market Cap 18.4B USD
Gross Margin
69%
Country US
Market Cap 204.9B USD
Gross Margin
56%
Country US
Market Cap 195.2B USD
Gross Margin
67%
Country US
Market Cap 146.7B USD
Gross Margin
64%
Country US
Market Cap 132.6B USD
Gross Margin
69%
Country IE
Market Cap 110.6B USD
Gross Margin
66%
Country US
Market Cap 64.7B USD
Gross Margin
45%
Country DE
Market Cap 55.6B EUR
Gross Margin
38%
Country CN
Market Cap 319.2B CNY
Gross Margin
65%
Country US
Market Cap 41.6B USD
Gross Margin
79%
Country US
Market Cap 37.7B USD
Gross Margin
41%
No Stocks Found

Insulet Corp
Glance View

Market Cap
18.4B USD
Industry
Health Care

Insulet Corporation is a pioneering medical device company, primarily recognized for its innovative Omnipod Insulin Management System, which revolutionizes diabetes care. Founded in 2000, Insulet has focused on developing patch pump technology that offers a seamless, tubeless insulin delivery solution for individuals with insulin-dependent diabetes. This cutting-edge product allows users to manage their insulin delivery discreetly and conveniently, enhancing their quality of life and simplifying the complex regimen of diabetes management. As the prevalence of diabetes continues to rise globally, Insulet stands at the forefront of meeting a substantial medical need, capturing a significant market share with its user-friendly technology. As an investor, understanding Insulet’s growth trajectory and market potential is essential. The company has witnessed consistent revenue growth, driven by increased adoption of its Omnipod systems, and has expanded its product portfolio to include a new generation of devices that offer even greater functionality. Insulet is also heavily investing in research and development to further innovate its offerings, positioning itself competitively in the fast-evolving diabetes care market. With strong industry partnerships and a commitment to enhancing user experience, Insulet represents not just a promising investment in healthcare technology but also a company that is fundamentally improving the lives of millions.

PODD Intrinsic Value
96.69 USD
Overvaluation 63%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
69.4%
=
Gross Profit
1.4B
/
Revenue
2B
What is the Gross Margin of Insulet Corp?

Based on Insulet Corp's most recent financial statements, the company has Gross Margin of 69.4%.